home news forum careers events suppliers solutions markets expos directories catalogs resources advertise contacts
 
News Page

The news
and
beyond the news
Index of news sources
All Africa Asia/Pacific Europe Latin America Middle East North America
  Topics
  Species
Archives
News archive 1997-2008
 

Annogen starts a collaboration with another leading agricultural multinational to research non-coding regulatory DNA using SuRE screening technology


Amsterdam, The Netherlands
January 26, 2023

Annogen, the Amsterdam based biotech company behind the SuRE™ technology for the functional annotation of the non-coding part of the genome, started a collaboration with another top agricultural science and technology company to test non-coding DNA fragments that are predicted to influence the expression of important crop traits. The project will focus on genome-wide regulatory profiles under normal and stimulatory conditions. The results are expected to provide possibilities to intentionally upregulate or downregulate the expression of important genes in crops.
 
Agricultural biotech companies are constantly working on ways to up- or down regulate gene expression to influence traits of crops. Annogen’s services and technology contribute to these efforts by identifying the non-coding elements in the genome that underlie gene expression and repression as well as by performing mutagenesis screens on these elements to analyze the impact of non-coding mutations on gene expression.              

While Annogen has its primary focus on medical applications like cell therapy and drug discovery, it has also established the applicability of its SuRE™ technology in animals and plants.
Joris van Arensbergen, founder and CEO, is pleased with another project in this field: “We now work with all the top tier agricultural firms, clearly illustrating the broad interest in harnessing the regulatory genome for crop improvement.”

About Annogen
At Annogen we use our SuRE™ technology to identify regulatory DNA elements to be used for controlled (therapeutic) gene expression for gene & cell therapy, as well as for recombinant protein production. In addition, we offer the AIM™ service to identify favorable gene insertions and their expression levels for more than 100,000 integrations in parallel. These approaches enables Research and Development to qualitatively interpret the non-coding genome in humans, animals and plants. For more information, please visit 
www.annogen.bio.

 



More news from: Annogen B.V.


Website: https://www.annogen.bio/

Published: January 26, 2023

The news item on this page is copyright by the organization where it originated
Fair use notice

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  Archive of the news section

 

 


Copyright @ 1992-2024 SeedQuest - All rights reserved